BC-1901S

• Description :

  BC-1901S is a proteasome-independent NRF2 activator and stabilizer. BC-1901S binds to DCAF1 (E3 ligase subunit) and disrupts NRF2/DCAF1 interaction, and activates NRF2 by inhibiting NRF2 ubiquitination in a KEAP1-independent manner. BC-1901S shows anti-inflammatory effect in a murine model of LPS-induced acute lung injury[1].

• UNSPSC :

  12352005

• Target :

  E1/E2/E3 Enzyme; Keap1-Nrf2

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; NF-κB

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/bc-1901s.html

• Purity :

  99.81

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1CCN(CC1)C2=NC(C3=CC(C)=CC=C3)=NC=C2)NC4=CC=C(C(Cl)=C4)F

• Molecular Formula :

  C23H22ClFN4O

• Molecular Weight :

  424.90

• References & Citations :

  [1]Chen Y, et al. A small molecule NRF2 activator BC-1901S ameliorates inflammation through DCAF1/NRF2 axis. Redox Biol. 2020 May;32:101485.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1358617-36-3]